The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Top amyloidosis updates from ASH 2025: the AQUARIUS trial, CAR T-cells, bispecifics & more!
In this video, Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, shares exciting data presented in the field of amyloidosis at ASH 2025, highlighting notable oral presentations, including the AQUARIUS study (NCT05250973). He also comments on novel therapies, such as bispecifics and CAR T-cells, which have shown promising results in the relapsed/refractory (R/R) setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
